Found: 56
Select item for more details and to access through your institution.
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00934-x
- By:
- Publication type:
- Article
Is non-alcoholic steatohepatitis a predisposing factor to porphyria cutanea tarda?
- Published in:
- Photodermatology, Photoimmunology & Photomedicine, 2013, v. 29, n. 2, p. 106, doi. 10.1111/phpp.12032
- By:
- Publication type:
- Article
Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.
- Published in:
- Nucleic Acids Research, 2013, v. 41, n. 16, p. e157, doi. 10.1093/nar/gkt601
- By:
- Publication type:
- Article
Trial designs and endpoints for immune therapies in multiple myeloma.
- Published in:
- American Journal of Hematology, 2023, v. 98, p. S35, doi. 10.1002/ajh.26753
- By:
- Publication type:
- Article
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02616
- By:
- Publication type:
- Article
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
A Network Analysis of Multiple Myeloma Related Gene Signatures.
- Published in:
- Cancers, 2019, v. 11, n. 10, p. 1452, doi. 10.3390/cancers11101452
- By:
- Publication type:
- Article
IFN-Alpha-Induced Cortical and Subcortical Glutamate Changes Assessed by Magnetic Resonance Spectroscopy.
- Published in:
- Neuropsychopharmacology, 2014, v. 39, n. 7, p. 1777, doi. 10.1038/npp.2014.25
- By:
- Publication type:
- Article
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/2040620720987075
- By:
- Publication type:
- Article
Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/ Refractory Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 4, p. 430, doi. 10.1016/j.clml.2013.03.015
- By:
- Publication type:
- Article
The Diabetes Prevention Program and the Metabolic Syndrome.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma.
- Published in:
- Advances in Hematology, 2012, p. 1, doi. 10.1155/2012/403648
- By:
- Publication type:
- Article
Outcomes Following Renal Transplantation in Patients with Chronic Hepatitis C Based on Severity of Fibrosis on Pre-Transplant Liver Biopsy.
- Published in:
- Saudi Journal of Kidney Diseases & Transplantation, 2013, v. 24, n. 4, p. 682, doi. 10.4103/1319-2442.113847
- By:
- Publication type:
- Article
Evaluation of direct-to-consumer low-volume lab tests in healthy adults.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Evaluation of direct-to-consumer low-volume lab tests in healthy adults.
- Published in:
- Journal of Clinical Investigation, 2016, v. 126, n. 5, p. 1734, doi. 10.1172/JCI86318
- By:
- Publication type:
- Article
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 293, p. 1, doi. 10.1126/scitranslmed.aaa5079
- By:
- Publication type:
- Article
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 413, doi. 10.1016/j.clml.2023.03.009
- By:
- Publication type:
- Article
Dupilumab in Multiple Myeloma: A Case Series.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 11, p. 853, doi. 10.1016/j.clml.2022.07.001
- By:
- Publication type:
- Article
The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 3, p. 192, doi. 10.1016/j.clml.2021.09.015
- By:
- Publication type:
- Article
Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 2, p. 129, doi. 10.1016/j.clml.2021.09.004
- By:
- Publication type:
- Article
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 12, p. e975, doi. 10.1016/j.clml.2021.07.014
- By:
- Publication type:
- Article
NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S171, doi. 10.1016/S2152-2650(21)02367-3
- By:
- Publication type:
- Article
P-155: Incidence, mitigation, and management of neurologic adverse events in CARTITUDE-2, a phase 2 study of ciltacabtagene autoleucel (cilta-cel) in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S120, doi. 10.1016/S2152-2650(21)02282-5
- By:
- Publication type:
- Article
P-090: BRAF V600E multiple myeloma patient salvaged with triple MAPK inhibition after CAR T relapse.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S88, doi. 10.1016/S2152-2650(21)02224-2
- By:
- Publication type:
- Article
P-102: Genomic and systemic metabolism differences associated with racial disparities in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S94, doi. 10.1016/S2152-2650(21)02236-9
- By:
- Publication type:
- Article
P-063: Pathogenic germline variants in hereditary cancer genes in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S73, doi. 10.1016/S2152-2650(21)02197-2
- By:
- Publication type:
- Article
OAB-053: Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S38, doi. 10.1016/S2152-2650(21)02133-9
- By:
- Publication type:
- Article
OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S30, doi. 10.1016/S2152-2650(21)02122-4
- By:
- Publication type:
- Article
MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S421, doi. 10.1016/S2152-2650(21)01945-5
- By:
- Publication type:
- Article
Poster: MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01568-8
- By:
- Publication type:
- Article
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. e470, doi. 10.1016/j.clml.2020.12.026
- By:
- Publication type:
- Article
Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
Mass cytometry reveals increase in marrow resident monocytes associated with response to daratumumab and pomalidomide.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e99, doi. 10.1016/j.clml.2019.09.162
- By:
- Publication type:
- Article
High dimensional profiling of the immune microenvironment in smoldering multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e27, doi. 10.1016/j.clml.2019.09.041
- By:
- Publication type:
- Article
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Integrative Network Analysis Identifies Novel Drivers of Pathogenesis and Progression in Newly Diagnosed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e13, doi. 10.1016/j.clml.2017.03.022
- By:
- Publication type:
- Article
Transmission of Eastern Equine Encephalitis Virus From an Organ Donor to 3 Transplant Recipients.
- Published in:
- Clinical Infectious Diseases, 2019, v. 69, n. 3, p. 450, doi. 10.1093/cid/ciy923
- By:
- Publication type:
- Article
Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 2, p. 1, doi. 10.1038/s41408-022-00629-1
- By:
- Publication type:
- Article
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 2, p. E51, doi. 10.1002/ajh.25695
- By:
- Publication type:
- Article
Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 10, p. 688, doi. 10.1002/ajh.21510
- By:
- Publication type:
- Article
Chronic parvovirus infection and G6PD deficiency masquerading as DiamondBlackfan anemia.
- Published in:
- American Journal of Hematology, 2005, v. 79, n. 1, p. 54, doi. 10.1002/ajh.20313
- By:
- Publication type:
- Article
The Effect of Novel Therapies in High-Molecular-Risk Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2017, v. 15, n. 11, p. 870
- By:
- Publication type:
- Article
Classical Hodgkin Lymphoma and Spontaneous Regression.
- Published in:
- Clinical Advances in Hematology & Oncology, 2012, v. 10, n. 11, p. 1
- By:
- Publication type:
- Article
A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 4, p. 471, doi. 10.1111/j.1365-2141.2011.08762.x
- By:
- Publication type:
- Article
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01330-3
- By:
- Publication type:
- Article